Meinacidin, a new antibacterial agent, blocked the synthesis of nicotinic acid and its amide in Bacillus subtilis cells. The inhibitory activity of the agent was reversed by nicotinic acid, its amide, or nicotinamide adenine dinucleotides, but not by Lkynurenine, L-3-hydroxykynurenine, L-hydroxyanthranilic acid, or quinolinic acid. These properties indicated that the antibiotic interferes with the conversion of quinolinic acid to nicotinate ribonucleotide by the enzyme quinolinate phosphoribosyltransferase. However, the activity of a purified preparation of this enzyme derived from a Pseudomonas strain was not impaired by the antibiotic. This suggested that, in B. subtilis, melinacidin interferes with a reaction which occurs before the formation of quinolinic acid in the biosynthetic pathway leading to nicotinic acid. Failure of quinolinic acid to reverse melinacidin inhibition in B. subtilis cultures might be due to insufficient penetration of the cell membranes by quinolinate.
Meinacidin, a new antibacterial agent, blocked the synthesis of nicotinic acid and its amide in Bacillus subtilis cells. The inhibitory activity of the agent was reversed by nicotinic acid, its amide, or nicotinamide adenine dinucleotides, but not by Lkynurenine, L-3-hydroxykynurenine, L-hydroxyanthranilic acid, or quinolinic acid. These properties indicated that the antibiotic interferes with the conversion of quinolinic acid to nicotinate ribonucleotide by the enzyme quinolinate phosphoribosyltransferase. However, the activity of a purified preparation of this enzyme derived from a Pseudomonas strain was not impaired by the antibiotic. This suggested that, in B. subtilis, melinacidin interferes with a reaction which occurs before the formation of quinolinic acid in the biosynthetic pathway leading to nicotinic acid. Failure of quinolinic acid to reverse melinacidin inhibition in B. subtilis cultures might be due to insufficient penetration of the cell membranes by quinolinate.
Melinacidin is a mixture of at least four closely related compounds isolated from the culture broth of the fungus Acrostalagmus cinnabarinus var. melinacidinus. The complex has the empirical formula CH6H,704N3S2 and crystallizes in the form of colorless needles which have very limited solubility in aqueous solutions. The preparation, isolation, characterization, and biological properties of this agent will be described elsewhere (Argoudelis and Reusser, in preparation). The agent inhibits gram-positive bacteria in vitro, but in mice is ineffective in the systemic treatment of experimental infections caused by gram-positive organisms. The antibiotic is very toxic in mice (tolerated dose, 2 to 3 mg/kg). This paper describes the effects of melinacidin on protein and nucleic acid synthesis in Bacillus subtilis cells and in cell-free Escherichia coli systems. In addition, it is demonstrated that melinacidin blocks the synthesis of nicotinic acid and its amide in B. subtilis. It is concluded that this property is the basis for the antibacterial activity of the antibiotic.
MATERIALS AND METHODS
B. subtilis strain 23 cells were grown in a medium containing the following ingredients, per liter: K2HPO4, 6 g; K2PO4, 14 g; MgSO4, 0.1 g; (NH4)2SO4, 2 g; sodium glutamate, 2 g, glucose monohydrate, 4 g; tryptone (Difco), 0.2 g. Shaken flasks containing 100 ml of medium were inoculated with 5 ml of seed derived from an overnight culture. The flasks were incubated on a rotary shaker at 37 C. Melinacidin was dissolved in dimethylformamide and was added in 0.1-ml portions per 100 ml of culture medium.
Cell growth was assessed by measuring the optical density (OD) of the bacterial suspensions at 570 nm.
The cellular protein and nucleic acid fractions of B. subtilis were isolated and assayed as described previously (5) . The cell-free polypeptide and nucleic acid biosynthetic E. coli systems were prepared as described by Reusser (5) .
Total nicotinic acid in the culture was determined according to the microbiological assay procedure of Snell and Wright (6) , with Lactobacillus plantarum ATCC 8014 as the assay organism. At cell harvest, enough concentrated H2SO4 was added to culture samples to make them 1 N with respect to H2SO4.
The samples were then autoclaved at 15 lb of pressure for 30 min to hydrolyze all of the nicotinic acidcontaining compounds to nicotinic acid. After hydrolysis, the samples were cooled, neutralized with concentrated NaOH, and assayed.
Pseudomonas strain ATCC 23269 was used for the preparation of quinolinate phosphoribosyltransferase. The organism was grown in a medium containing the following ingredients, per liter of deionized water: NaH2PO4, 0.5 g; K2HPO4, 1.5 g; MgSO4, 0.15 g; quinolinic acid, 1.5 g; the pH was adjusted to 7.0 with concentrated NaOH (4). Shaken flasks containing 100 ml of medium were inoculated with 5 ml of seed derived from a culture grown overnight. The flasks were incubated at 28 C for 18 hr. Cells were recovered by centrifugation and were stored at -20 C until used.
A 6-g amount of cells (wet weight) was suspended in 24 ml of 0. addition of the agent. After this time, 1 ,ug of melinacidin per ml caused virtually complete cessation of cell growth; 0.1 ,ug of melinacidin per ml caused less inhibition.
Partial inhibition of cellular protein synthesis was apparent immediately after addition of melinacidin at all concentrations (0.1, 1, 5 ,g/ml) tested (Fig. 2) . After approximately 50 min of exposure of the cells to 1 Mg of drug per ml, protein synthesis ceased completely; however, some synthesis persisted in the presence of either 5 or 0.1 ,g/ml for up to 2 hr.
Partial inhibition of cellular deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis took place immediately after addition of 5 Mug of melinacidin per ml (Fig. 2) . Drug concentrations of 1 or 0.1 MAg/ml stimulated nucleic acid synthesis slightly during the first 40 min after addition of the antibiotic. After this period, both DNA and RNA synthesis became gradually impaired. Complete cessation occurred after 40 to 60 min m the presence of 1 Mg of antibiotic per ml; 5 or 0.1 Mg of drug per ml did not block nucleic acid synthesis completely during the duration of the experiment (2 hr).
Effects of melinacidin on macromolecular biosynthetic processes in cell-free systems. Antibiotic concentrations ranging from 5 to 40 Mug/ml did not interfere significantly with the polynucleotide-mediated incorporation of '4C-phenylalanine or '4C-proline in the amino acid incorporation systems prepared as described by Reusser (5 Reversal of melinacidin inhibition by cellular metabolites (vitamins, amino acids, etc.). The results discussed thus far indicated that the addition of melinacidin at first causes only partial inhibition of cell growth. This phenomenon was apparent even though relatively high antibiotic concentrations were used. Substantial net synthesis of protein and nucleic acid occurred during the phase immediately after addition of drug. None of the cell-free macromolecular biosynthetic systems was inhibited by the drug. The limited continuation of cell growth after addition of melinacidin suggested that the culture is gradually depleting an essential cell metabolite whose de novo synthesis is blocked by the antibiotic.
Mixtures of amino acids, purines, pyrimidines, or vitamins were thus added to cultures contain- ing melinacidin in an attempt to reverse the inhibitory activity of melinacidin. Of all the metabolites tested, only nicotinamide reversed the antibacterial activity of melinacidin in B. subtilis (Fig. 3) . A concentration of 1 jig of nicotinamide per ml caused substantial reversal of the growth inhibition induced by 5 ,ug of melinacidin per ml. When nicotinamide was added after cessation of cell growth following drug addition (3.5 hr after addition of the drug in the experiment shown in Fig. 3) (Fig. 4) . It is of interest to note that, at a concentration of0.001 ,ug/ml, nicotinamide was able to induce some reversal of melinacidin inhibition when the antibiotic was present at a concentration of 5 l,g/ml (ratio of nicotinamide to melinacidin was 1: 5,000). Maximal reversal was achieved at a nicotinamide concentration of 0.1 ug/ml. Cell growth at this concentration was still not quite as abundant as in the control culture.
When the concentration of melinacidin varied in the presence of a constant amount of nicotinamide, the extent of reversal was found to be much greater at 0.1 or 5 ug of melinacidin per ml than at 1 Mg of melinacidin per ml (Fig. 5) (Fig. 6) . On rnl. This indicates that the antibiotic blocks the synthesis of nicotinic acid or its amide and does not merely serve as an antimetabolite of the vitamin.
Quantitative assays of the nicotinic acid formed in the cultures established that the synthesis of this vitamin ceases immediately upon addition of melinacidin. No destruction of nicotinic acid is apparent.
In mammals and fungi, nicotinic acid arises from tryptophan as a precursor. In bacteria, nicotinic acid is formed via the condensation of a 4-carbon dicarboxylic acid (succinic acid, aspartic acid) with a 3-carbon compound (glycerol).
One or several unknown steps lead to the formation of quinolinic acid which is then converted to nicotinate ribonucleotide. Thus, quinolinic acid occurs as a common precursor in both the bacterial and mammalian pathway (1, 2) . Several intermediates occurring within the mammalian pathway (L-kynurenine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid) as well as quinolinic acid did not cause reversal of melinacidin inhibition. This suggests that the antibiotic interferes with nicotinic acid synthesis at a point after the formation of quinolinate but before the formation of nicotinate ribonucleotide. Specifically, these results suggest that the antibiotic inhibits the function of quinolinate phosphoribosyltransferase.This enzyme catalyzes the reaction quinolinate + PRPP --nicotinate ribonucleotide. Inhibition of this reaction may account for the toxicity of the antibiotic in mammals and in bacteria. However, this reaction step, studied with a purified enzyme preparation derived from a Pseudomonas strain, remained totally unaffected by the antibiotic.
The proposed pathways leading to the synthesis of NAD in bacteria are shown in the scheme below (2, 3): glycerol + succinate or aspartate -+ -* quinc I activity in crude B. subtilis extracts, this possibility cannot be entirely ruled out.
In addition, synthesis of nicotinic acid in B. subtilis and other bacteria susceptible to the antibiotic may proceed via slightly different pathways than those postulated for most bacteria and a yet unknown step may be blocked.
nicotinic acid -* nicotinate ribonucleotide --deamido-NAD T (nicotinate pathway) nicotinamide -* nicotinamideribonucleotide (nicotinamide pathway)
NAD
The fact that both nicotinic acid and its amide are equally active in reversing melinacidin inhibition suggests that the nicotinate pathway and probably also the nicotinamide pathway are functional in B. subtilis, unless nicotinamide enters the nicotinate pathway via deamination by nicotinamide deaminase. Thus, I postulate that melinacidin blocks nicotinic acid synthesis in susceptible bacteria at a reaction step occurring before the formation of quinolinic acid. Failure of quinolinic acid to reverse melinacidin inhibition in B. subtilis may be due to the inability of quinolinate to penetrate the cell membranes in an amount sufficient to cause effective reversal. A similar lack of effective penetration of quinolinate has been observed by Hayaishi et al. (2) in lver.
It must also be considered that the two quinolinate phosphoribosyltransferases present in B. subtilis and Pseudomonas may differ sufficiently in their structure to render only the B. subtilis enzyme susceptible to inhibition by the antibiotic.
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